<DOC>
	<DOCNO>NCT02036970</DOCNO>
	<brief_summary>This study assess safety efficacy bardoxolone methyl relative placebo patient pulmonary hypertension determine recommend dose range , evaluate change baseline 6-minute walk distance ( 6MWD ) determine effect Bardoxolone methyl pulmonary hypertension associate connective tissue disease , interstitial lung disease , idiopathic etiology , include subset patient WHO Group III WHO Group V PH follow 16 week study participation .</brief_summary>
	<brief_title>Bardoxolone Methyl Evaluation Patients With Pulmonary Hypertension ( PH ) - LARIAT</brief_title>
	<detailed_description>The molecular pharmacological effect bardoxolone methyl broad induction Nrf2 suppression NF-κB . Bardoxolone methyl may therefore address multiple facet pathophysiology PH suppress activation proinflammatory mediator , enhances endothelial NO bioavailability , improve metabolic dysfunction , suppress vascular proliferation , prevents maladaptive remodel . Furthermore , exist therapy primarily target smooth muscle cell , bardoxolone methyl target multiple cell type relevant PH , include endothelial cell , smooth muscle cell , macrophage . This two-part study . Part 1 : Part 1 study include dose-ranging phase dose-titration phase . Part 2 ( extension period ) : All patient Part 1 complete 16-week treatment period plan eligible continue directly extension period evaluate intermediate long-term safety efficacy bardoxolone methyl .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>1 . Adult male female patient ≥ 18 ≤ 75 year age upon study consent ; 2 . BMI &gt; 18.5 kg/m² 3 . Symptomatic pulmonary hypertension WHO class II III ; 4. WHO Group I , III , V PH accord follow criterion : 1 . If diagnose WHO Group I PAH , follow subtypes : Idiopathic heritable PAH ; PAH associate connective tissue disease ; PAH associate simple , congenital systemictopulmonary shunt least 1 year follow shunt repair ; PAH associate anorexigen druginduced toxicity ; PAH associate human immunodeficiency virus ( HIV ) ; 2 . If WHO Group III PH primary diagnosis must one follow subtypes : Connective tissue disease associate ILD ( CTDILD ) ; Idiopathic pulmonary fibrosis ( IPF ) ; Nonspecific interstitial pneumonia ( NSIP ) ; 3 . If WHO Group V PH patient must diagnose sarcoidosis ; 5 . Had diagnostic right heart catheterization perform document within 36 month prior Day 1 confirm diagnosis PH 6 . If WHO Group I , receive three ( 3 ) FDAapproved diseasespecific PAH therapy except intravenous ( iv ) prostacyclin/prostacyclin analogue . PAH therapy must stable dose least 90 day prior Day 1 ; 7 . Has adequate kidney function define estimate glomerular filtration rate ( eGFR ) ≥ 45 mL/min/1.73 m2 use Modification Diet Renal Disease ( MDRD ) 4variable formula ; 1 . Participation interventional clinical study involve pharmaceutical product test used way different approve form use unapproved indication within 30 day prior Day 1 ; 2 . Initiation exercise program cardiopulmonary rehabilitation within 3 month ( 90 day ) prior Day 1 plan initiation Part 1 study ; 3 . Stopped receive PH chronic therapy within 60 day prior Day 1 ; 4 . Requirement receipt intravenous inotropes within 30 day prior Day 1 ; 5 . Has uncontrolled systemic hypertension evidence sit systolic blood pressure ( BP ) &gt; 160 mm Hg sit diastolic blood pressure &gt; 100 mm Hg Screening period rest ; 6 . Has systolic BP &lt; 90 mm Hg Screening period rest ; 7. WHO Group III V patient rest require supplemental oxygen rate &gt; 4 L/min peripheral capillary oxygen saturation level &lt; 92 % ; 8 . Has history clinically significant leftsided heart disease and/or clinically significant cardiac disease , include limited following : 1 . Congenital acquire valvular disease clinically significant apart tricuspid valvular insufficiency due pulmonary hypertension ; 2 . Pericardial constriction ; 3 . Restrictive congestive cardiomyopathy ; 4 . Left ventricular ejection fraction &lt; 40 % per echocardiogram ( ECHO ) within 60 day Day 1 ; 5 . Any current prior history symptomatic coronary disease ( prior myocardial infarction , percutaneous coronary intervention , coronary artery bypass graft surgery , anginal chest pain ) ; 9 . Acutely decompensated heart failure within 30 day prior Day 1 , per Investigator assessment ; 10 . History atrial septostomy within 180 day prior Day 1 ; 11 . History obstructive sleep apnea untreated ; 12 . Has history portal hypertension chronic liver disease , include hepatitis B and/or hepatitis C ( evidence recent infection and/or active virus replication ) define mild severe hepatic impairment ( ChildPugh Class AC ) ; 13 . Serum aminotransferase ( ALT AST ) level &gt; upper limit normal ( ULN ) Screening ; 14 . For patient HIVassociated PAH , follow : 1 . Concomitant active opportunistic infection within 180 day prior Screening ; 2 . Detectable viral load within 90 day prior Screening ; 3 . Cluster designation ( CD+ ) Tcell count &lt; 200 mm3 within 90 day prior Screening ; 4 . Changes antiretroviral regimen within 90 day prior Screening ; 5 . Using inhaled pentamidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>Bardoxolone methyl</keyword>
	<keyword>6-minute walk distance</keyword>
	<keyword>CDDO-me</keyword>
	<keyword>RTA 402</keyword>
	<keyword>Pulmonary Hypertension</keyword>
</DOC>